NDAORALTABLETPriority Review
Approved
Jul 2015
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TECHNIVIE is a fixed-dose combination oral tablet containing ombitasvir, paritaprevir, and ritonavir, approved in 2015 for hepatitis C virus (HCV) treatment. It represents a direct-acting antiviral (DAA) regimen targeting multiple steps of the HCV replication cycle. The combination blocks viral protease and NS5A protein, enabling cure-oriented therapy for select HCV genotypes.
Peak5.6 years to LOE
Product is in peak commercial phase with stable market penetration; brand teams are focused on lifecycle extension and maintaining share against newer DAA regimens.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TECHNIVIE offers limited new hiring velocity (0 linked jobs) but provides solid mid-career stability for commercial and medical affairs professionals. This product is best suited for professionals seeking deep disease expertise in viral hepatology and managed care negotiation rather than early-stage drug development or launch excitement.
Brand ManagerField Sales Representative
Worked on TECHNIVIE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.